BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Uterine cancer AND BUB1B, BUBR1, 701, ENSG00000156970, SSK1, BUB1beta, MAD3L, hBUBR1, Bub1A, O60566 AND Prognosis
11 results:

  • 1. BUB1, bub1b, CCNA2, and CDCA8, along with miR-524-5p, as clinically relevant biomarkers for the diagnosis and treatment of endometrial carcinoma.
    Hao Q; Wu H; Liu E; Wang L
    BMC Cancer; 2023 Oct; 23(1):995. PubMed ID: 37853361
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. ASPM, CDC20, DLGAP5, bub1b, CDCA8, and NCAPG May Serve as Diagnostic and Prognostic Biomarkers in Endometrial Carcinoma.
    Zhang Q; Wang Y; Xue F
    Genet Res (Camb); 2022; 2022():3217248. PubMed ID: 36186000
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Lymphovascular space invasion in endometrial carcinoma: A prognostic factor independent from molecular signature.
    Raffone A; Travaglino A; Raimondo D; Neola D; Maletta M; Santoro A; Insabato L; Casadio P; Fanfani F; Zannoni GF; Zullo F; Seracchioli R; Mollo A
    Gynecol Oncol; 2022 Apr; 165(1):192-197. PubMed ID: 35078650
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Post-recurrence survival in patients with cervical cancer.
    Cibula D; Dostálek L; Jarkovsky J; Mom CH; Lopez A; Falconer H; Scambia G; Ayhan A; Kim SH; Isla Ortiz D; Klat J; Obermair A; Di Martino G; Pareja R; Manchanda R; Kosťun J; Dos Reis R; Meydanli MM; Odetto D; Laky R; Zapardiel I; Weinberger V; Benešová K; Borčinová M; Cardenas F; Wallin E; Pedone Anchora L; Akilli H; Abu-Rustum NR; Barquet-Muñoz SA; Javůrková V; Fischerová D; van Lonkhuijzen LRCW
    Gynecol Oncol; 2022 Feb; 164(2):362-369. PubMed ID: 34955236
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma.
    Raffone A; Travaglino A; Raimondo D; Neola D; Renzulli F; Santoro A; Insabato L; Casadio P; Zannoni GF; Zullo F; Mollo A; Seracchioli R
    Gynecol Oncol; 2021 Aug; 162(2):401-406. PubMed ID: 34088515
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Combined dynamic contrast enhanced MRI parameter with clinical factors predict the survival of concurrent chemo-radiotherapy in patients with 2018 FIGO IIICr stage cervical cancer.
    Qin F; Pang H; Ma J; Zhao M; Jiang X; Tong R; Yu T; Luo Y; Dong Y
    Eur J Radiol; 2021 Aug; 141():109787. PubMed ID: 34051683
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Nomograms predicting the overall survival and cancer-specific survival of patients with stage IIIC1 cervical cancer.
    Feng Y; Wang Y; Xie Y; Wu S; Li Y; Li M
    BMC Cancer; 2021 Apr; 21(1):450. PubMed ID: 33892663
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Risk of Gynecologic cancer as Second versus First Primary cancer in Japan.
    Ogawa C; Nakamura K; Matsuoka H; Matsubara Y; Haraga J; Masuyama H
    Acta Med Okayama; 2020 Apr; 74(2):109-114. PubMed ID: 32341584
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Prognostic value of metabolic parameters determined by preoperative ¹⁸F-FDG PET/CT in patients with uterine carcinosarcoma.
    Lee HJ; Lee JJ; Park JY; Kim JH; Kim YM; Kim YT; Nam JH
    J Gynecol Oncol; 2017 Jul; 28(4):e43. PubMed ID: 28541634
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Analysis of Conservative Surgical Treatment and prognosis of Microinvasive Squamous Cell Carcinoma of the Cervix Stage IA1: Results of Follow-Up to 20 Years.
    Hartman CA; Teixeira JC; Barbosa SB; Figueiredo SM; Andrade LA; Bastos JF
    Int J Gynecol Cancer; 2017 Feb; 27(2):357-363. PubMed ID: 27984378
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. [Evaluation of postoperative bladder function and prognosis after modified nerve sparing radical hysterectomy].
    Wenwen W; Bin L; Jing Z; Gongyi Z; Yeduo Y; Hongmei Z; Xiaoguang L; Lingying W
    Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):341-7. PubMed ID: 25030730
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.